We are aware that India is currently administering Covishield, manufactured by the Serum Institute of India, and Bharat Biotech’s Covaxin. Along with them, the country has also given nod to Sputnik V, which has an efficiency of over 91 per cent.
As per reports, India is holding discussions with pharmaceutical giant Pfizer to buy the vaccine from them. Reports suggest that the company is expected to sell 50 million doses of its coronavirus vaccine to India by the 3rd quarter of this fiscal year.
The ongoing negotiations between the company and the central government are said to be heading towards a positive conclusion.
The vaccines will be ready for purchase by the government only for its Covid immunisation programme. Notably, the vaccine by Pfizer is fairly expensive when compared to other vaccines in the market.